Publications by authors named "Mitsutoshi Toda"
Article Synopsis
- The study aimed to explore the levels of lipoprotein(a) (Lp(a)) and its link to atherosclerotic cardiovascular disease (ASCVD) in high-risk Japanese patients, using health insurance database data.
- Researchers analyzed data from patients who qualified for ASCVD prevention and had Lp(a) tests, separating them into three risk groups and collecting relevant health data.
- Findings revealed that only a small percentage of patients were tested for Lp(a), yet those with higher levels of Lp(a) showed a greater occurrence of ASCVD, raising concerns about the low testing rates in this high-risk population.
Article Synopsis
- A clinical pathway was implemented in Nagasaki hospitals for managing LDL cholesterol (LDL-C) after acute myocardial infarction (AMI) to improve patient outcomes.
- The study found that the percentage of patients achieving the LDL-C target of <70 mg/dL increased from 37.2% to 54.6% after the pathway was introduced.
- Overall, the implementation of this pathway significantly enhanced lipid-lowering therapy effectiveness in hospitals performing percutaneous coronary interventions (PCI).
The rapid rise in the prevalence of type 2 diabetes mellitus (T2DM) poses a huge healthcare burden across the world. Although there are several antihyperglycaemic agents (AHAs) available including addition of new drug classes to the treatment algorithm, more than 50% of patients with T2DM do not achieve glycaemic targets, suggesting an urgent need for treatment strategies focusing on prevention and progression of T2DM and its long-term complications. Lifestyle changes including implementation of healthy diet and physical activity are cornerstones for the management of T2DM.
View Article and Find Full Text PDFArticle Synopsis
- Vildagliptin is used to treat type 2 diabetes mellitus (T2DM) in Japanese patients, but its effects on diabetic complications had not been studied before this research.
- In a 2-year study involving over 19,000 patients, the incidence rates of macro- and microvascular complications were found to be low, particularly in those who maintained better glycemic control (lower HbA1c levels).
- The study concluded that vildagliptin does not exacerbate diabetic complications, and good blood sugar management is linked to reduced risks of such complications.